Cornel N. Stanciu, MD, MRO

In this journal club, a medical student and an addiction psychiatrist review a thematic analysis of successful prevention efforts in states with declining rates of opioid-related overdose deaths.

Only a few digital therapeutics are currently FDA approved. What options are available and how can they best be leveraged for the benefit of patients?

A new study provides guidance for clinicians discussing the risks of ADHD medications with their pregnant patients.

Are people with high "neuroticism-depression" likely to drink more than the average person when stressed? We may be getting closer to the answer.

Research zeroes in on how frailty impacts depression treatment in elderly patients.

Are patients with depression and substance use disorder getting an appropriate level of care? Our Journal Club piece investigates.

There are no human clinical trials or even case reports to assess or describe the efficacy of this very complex botanical. Here’s what we know.

COVID-19 is the most devastating pandemic in recent history, and it has taken a huge toll. Here are some tips to take into consideration when advocating for your safety and the safety of your patients.

The authors explore adjunctive treatments for MDD and their impact on overall medical costs and health care utilization.

Addiction is a disease of social nature. The interruption of normalcy, even for those in a period of sobriety, can be especially hard on patients with addiction.

The authors examine recent literature in order to assist psychiatrists in evaluating the findings and determining how to best put research findings into real-world practice.

Patients often have questions concerning integrative therapeutic modalities, and it is important to know the existing evidence as well as limitations of current research.

Consumption of cannabis during pregnancy results in a host of problems, including cannabinoid placental crossing and accumulation in the fetal brain as well as other organs.

A patient with refractory MDD continued to suffer and feel as though her life was turned upside down, despite treatment. Learn the outcome of the case.

As we learn more about the immune system and its involvement in psychiatric conditions, including depression, LDN is an intriguing tool to keep in mind and for future exploration.

Tips for advocating for yourself and the safety of your patients.

Mounting evidence shows the endogenous opioid system is a potential therapeutic target for mood disorders, yet questions remain.

As the COVID-19 pandemic continues to affect the country, SAMHSA and the DEA allow for flexibility in addressing the needs of patients with opioid use disorder.

Psychiatrists are exploring ways to best serve their patients while complying with the medicolegal restrictions of the coronavirus. Here: approaches to best leverage telemedicine for patients with ADHD.

Chronotherapy presents a unique tool to add to the armamentarium of available modalities for management of non-seasonal depression. Clinicians should be familiar with its application and be able to implement it in recalcitrant sufferers.

This research update underscores the need to be well versed in the data in order to have meaningful conversations with our patients who are cannabis users or contemplate use.

Public endorsement for potential benefits of the marijuana plant is at an all-time high, even in vulnerable populations, such as pregnant women.

This CME discusses the opioid-like effects of loperamide and kratom and raises awareness of potential dangers associated with use.

More than 6 out of 10 deaths involve prescribed opioids. The authors address guidelines for who should (and who should not) receive a naloxone prescription.

The authors use a 3-step process to identify and evaluate published research with findings that are ready for-and that have a direct bearing on-clinical practice.